Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Penn Cancer CME Event
Neuro-Oncology Brain Tumors Symposium 2024
FRIDAY, JANUARY 26, 2024
11:20 am – Overcoming Barriers to Extend Survival: Promising results of clinical trials for glioblastoma
https://vimeopro.com/ajievents/brain2024/video/910907300
Thanks for sharing Chiugray. You are right and Ex is wrong. DCVax-L is considered an ATMP (Advanced Therapy Medicinal Product) and not a Biosimilar ATMP. DCVax-L manufactured in a closed system is not a “Biosimilar DCVax-L”. Ex statement is incorrect. Guidance on biosimilars does not apply to DCVax-L, as it is not a biosimilar product.
Here is the definition of biosimilar ATMPs:
Honor to have @EladLevyMD , Dr. Linda Liau, Dr. Edward Chang, and Dr. Ziya Gokaslan as our honored speakers at our 51st annual meeting #TANS2024 pic.twitter.com/yPbRa7Y34q
— Peter Kan (@PeterKa80460001) February 3, 2024
In our brain tumour campaigning blog this week there are questions from @PaulJSweeney and @DanCardenMP, a blood test breakthrough and we talk to our ‘critical friends’ ➡️ https://t.co/Vbwj5iO2Hc #BrainTumourResearch #Campaigning #BrainTumour pic.twitter.com/WOj8JUg3CD
— Brain Tumour Research (@braintumourrsch) January 28, 2024
Patients could benefit from the blood test breakthrough in as little as two years. The accessibility and widespread adoption of the blood test may influence how quickly it becomes integrated into standard diagnostic procedures and impacts patient care.
The blood test and DCVax-L may potentially complement each other, with the blood test aiding in diagnosis and patient selection, while DCVax-L addresses the specific immune response against the tumor.
Have you listened to the presentation and viewed the slides?
The 11th Neuro-Oncology #braintumor Symposium.
— Steven Brem (@StevenBremMD) January 26, 2024
We have attendees From Around the World, 16 countries and 30 states.
It is still possible for you to register and receive our educational materials for up to one year. Click below to register.https://t.co/oouqj4yaza pic.twitter.com/IZWgbijIxK
Ex, I think you are able to construct a reasonably accurate OS curve (between 0 and 36 months after surgery) for the placebo group (n=99) based on the substantial amount of available data. ( 2017-2018 OS data and JAMA data)
The 11th Neuro-Oncology #braintumor Symposium.
— Steven Brem (@StevenBremMD) January 26, 2024
We have attendees From Around the World, 16 countries and 30 states.
It is still possible for you to register and receive our educational materials for up to one year. Click below to register.https://t.co/oouqj4yaza pic.twitter.com/IZWgbijIxK
StonkMaster,
Prof. Steven Brem was talking about our DCVax-L trial. So Nort… is Northwest Biotherapeutics.
I was surprised by his reaction, as if he was disclosing sensitive information. I don’t consider the company’s name to be a sensitive or confidential matter. So, I wonder why he didn’t mention the company’s name.
The link was posted by pgsd two days ago.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173698774
https://www.med.upenn.edu/brain2024/agenda.html
⬇️ Last Chance! ⬇️
— Penn Neurosurgery (@PennNSG) January 25, 2024
Tomorrow we have our Neuro-Oncology Brain Tumor Symposium where speakers will be covering the latest advances for treating brain tumors. Genetic, translational, and clinical research will also be featured!
Register Here: https://t.co/COgyqZbfPJ pic.twitter.com/fGeWeBmFHG
Happy 81st Birthday Gary. Wishing you a day filled with joy, good health, and wonderful memories. May this year bring you continued happiness and fulfillment. Cheers to another fantastic year ahead!
Penn Cancer CME Event
Neuro-Oncology Brain Tumors Symposium 2024
FRIDAY, JANUARY 26, 2024
11:20 am – Overcoming Barriers to Extend Survival: Promising results of clinical trials for glioblastoma
Dendritic Cell Vaccine – for nd-GBM and rGBM.
Prof. Steven Brem:
Published: 12 January 2024
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.
https://www.nature.com/articles/s43018-023-00709-6
Kudos to @StephenBagleyMD, Zev Binder, Donald M. O'Rourke and our team of collaborators for the publication today @NatureCancer on the Phase 1 study of CAR T cell therapy with #pembrolizumab, showing biological activity in the #TME, but limited clinical efficacy, pointing to… pic.twitter.com/sLr5HyoMfd
— Steven Brem (@StevenBremMD) January 12, 2024
The UK's current rank of 22 out of 29 comparable countries for brain cancer survival is a disappointing statistic.
It underscores the urgency to approve innovative treatments like DCVax-L. The benefits of this groundbreaking immunotherapy for GBM and recurrent GBM could offer hope for improved outcomes and contribute to raising the survival rates in the UK.
The survival rates for liver, lung, brain, oesophagus, stomach, and pancreas cancers are low everywhere.
— Brain Tumour Research (@braintumourrsch) January 11, 2024
But they are even lower if you're diagnosed in the UK.
We can do more.
We can tackle the #DeadlyCancerGap 💪 #BrainTumourResearch pic.twitter.com/iX1uY0falj
StonkMaster,
The Sawston facility contains a total of 88,345 square feet on two floors. The initial production capacity comprises two manufacturing suites, occupying approximately 4,400 square feet (Phase 1A).These two suites are anticipated to have potential capacity to produce dendritic vaccines for up to 40 to 50 patients per month.
I anticipate that Phase 1B's construction is very similar to that of Phase 1A, suggesting that the additional suites will likely have a similar potential capacity to produce vaccines for up to 40 to 50 patients per month
Does anyone have any information about Linda Liau's presentation at the 6th annual Student Neurosurgery & Neurology Research Conference?
(1/3) Huge thanks to everyone who joined us today for SNRC 2024! It was a pleasure for us to host the conference and hear about your incredible research going on around the world! Special thanks to our speakers Dr. Linda Liau, Dr. Michael Rubin, Dr. Adetokunbo Oyelese, pic.twitter.com/Oo67QfOzZm
— Anna Kimata (@anna_kimata) January 6, 2024
Great job, Sentiment. Awesome summary. Thanks!
Great story.
Kat was diagnosed with GBM in April 2013. She needed to undertake radiotherapy and chemotherapy to shrink the tumour before she could do surgery. Kat started radiotherapy in October 2013 and by December there had been a significant reduction in the size of the tumour, but by April 2014 the tumour had once again started to grow. The severity of her symptoms led to her being shedulded for a debulking surgery at NHNN.
Kat and her husband Jason got in touch with a specialist in clinical trials and managed to get Kat onto a trial which used a protein inhibitor called FAK. It worked for another year.
Kat then went on another round of chemo and followed this with an awake craniotomy.
The doctors managed to remove more than 80% of tumour. (October 29, 2015)
Kat’s family and friends raised money in the community to have the tissues sent to America and to be prepared for experimental DCVax-L immunotherapy.
The next year Kat received DCVax-L in conjunction with chemotherapy and after taking them for almost nine months she was declared tumour-free.
After nearly a year of minimal chemotherapy and zero tumour activity, they found out there was a flare on her right frontal lobe – the doctors were concerned it could be new progression.
The flare-up on the right side was not a tumour at all, but a reaction to the immunotherapy.
Kat is now a 10-year GBM survivor and she’s still doing well.
Notice Kat Charles picture and story on the wall of Northwest Biotherapeutics’ booth at the recent SNO 2023 Conference in Vancouver Canada.
It was great to see the presence of $NWBO at SNO 2023 in Vancouver Canada. Professor Ashkan from King's College Hospital had a great talk at the end of last night. Hopefully #DCVax will soon become the new standard of care for GBM patients worldwide. pic.twitter.com/9kh99tS7zB
— NorthVanVic (@NorthVanVic) November 18, 2023
Great post flipper44
flipper 44,
I was wrong. I realize now that I was misled by the air date of the interview, which I believed was recent due to the December 29 airing on the Big Biz Show. I apologize for any confusion caused by my post earlier. I 'll make sure to double-check details more thoroughly in the future. Thank you again for your understanding.
hope4patients,
Thank you for pointing that out. I appreciate your correction. I realize now that I was misled by the air date of the interview, which I believed was recent due to the December 29 airing on the Big Biz Show. I apologize for any confusion caused by my post earlier. Your clarification helps to ensure accurate information. I 'll make sure to double-check details more thoroughly in the future. Thank you again for your understanding.
I believe the interview was recorded after the MAA submission. I quess this was Part 1 of the interview, and I anticipate receiving Part 2 in the coming days, just as they did last time.
Thanks for sharing Peter.
I've been closely following Sam's heartbreaking story for a while now.
Here's the latest update:
Les Goldman is on the Big Biz Show discussing proteomics, but he's not revealing anything new IMO.
Big Biz Show - 12-29-23
Min 21.45s
https://www.biztalkradio.com/players/individuals/
So sorry to hear this, Smokey21. I wish you all the best. Merry Christmas.
Generous Christmas gift.
Thanks for sharing ATLnsider.
Kristyn Power, CFA
Program Director, Canada at Northwest Biotherapeutics
1d
"Hope for Wayne" - Stage 4 Glioblastoma Multiforme.
https://www.gofundme.com/f/hope-for-wayne-stage-4-glioblastoma-multiforme
Stonkmaster,
Thanks for sharing. This is great news for newly diagnosed and recurrent Glioblastoma patients. Now the train is running.
Perhaps coincidentally this Freedom of Information response from the MHRA - week commencing 20 June 2022- published today.
ae kusterer,
thanks for sharing.
The Year in Review by Derek Thomas MP.
This week is a review of 2023 –“ the past year has been our most impactful” says the Chair of the APPGBT ➡️ https://t.co/rmxdRtIZWm #APPGBT #Campaigning #BrainTumours @hugh1eadams pic.twitter.com/LdGoB65nnZ
— Brain Tumour Research (@braintumourrsch) December 17, 2023